11 September 2015 - UK patients with idiopathic pulmonary fibrosis (IPF) could soon get routine access to the first targeted therapy on the National Health Service in England and Wales, after cost regulators issued a preliminary green light for Boehringer Ingelheim’s Ofev (nintedanib esylate).

In draft guidance out today (Friday), the National Institute for Health and Care Excellence supports the use of Ofev in patients with IPF, but only if the person has a forced vital capacity between 50% and 80% predicted and the drug is provided with the discount agreed in the patient access scheme.

For more details, go to: http://www.pharmatimes.com/Article/15-09-11/NICE_nod_for_BI_s_lung-scarring_drug_Ofev.aspx